Cite

    Nemunaitis, J., Papai, Z., Léna, H., Losonczy, G., Forget, F., Chouaid, C., Szczesna, A., Gervais, R., Ottensmeier, C., Beck, J., Kazarnowicz, A., Westeel, V., Debieuvre, D., Madroszyk, A., Felip, E., Limacher, J., & Quoix, E. (2015). tG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial. Journal for immunotherapy of cancer, 3(2), 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x000336